Corporate Presentation to Highlight Company’s Gene Therapies for Cancer and Diabetes
Live panel discussion will explore considerations with respect to positioning of cell-based and other emerging immunotherapy platforms in solid tumors
Company achieves major milestones in clinical development programs in 2022 Patient treatment in Acclaim-2 clinical trial commences
Designed and Secured by Barsec